Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab vs Chemotherapy in R/R Classical Hodgkin Lymphoma
NCT05518318Phase 3Unknown
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of zimberelimab in classical Hodgkin lymphoma (cHL), sponsored by Guangzhou Gloria Biosciences Co., Ltd.. Status: unknown.
02
Drugs
zimberelimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05518318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518318.